Karyopharm Therapeutics (KPTI) Operating Income (2012 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Operating Income came in at -$17.8 million in Q4 2025, up 42.96% YoY from -$12.5 million in Q4 2024, and down 17.24% on a QoQ basis from -$15.2 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Operating Income (2012 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 14 years of Operating Income data on file, last reported at -$17.8 million in Q4 2025.
- Quarterly Operating Income rose 42.96% year-over-year to -$17.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$90.7 million (up 24.06% YoY) and the FY2025 annual result came in at -$90.7 million, up 24.06% from the prior year.
- Operating Income eased to -$17.8 million in Q4 2025, from -$15.2 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $47.0 million in Q4 2021 to a low of -$52.4 million in Q1 2021.
- A 5-year average of -$29.0 million and a median of -$31.3 million in 2023 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2021 — Operating Income jumped 226.7% — and 2022, when it plunged 172.12%.
- Tracing KPTI's Operating Income over 5 years: stood at $47.0 million in 2021, then tumbled by 172.12% to -$33.9 million in 2022, then dropped by 11.63% to -$37.8 million in 2023, then increased by 17.26% to -$31.3 million in 2024, then soared by 42.96% to -$17.8 million in 2025.
- The last three Operating Income figures came in at -$17.8 million (Q4 2025), -$15.2 million (Q3 2025), and -$24.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | -22.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.53 Mn |
| Dec 31, 2025 | -17.84 Mn |
| Sep 30, 2025 | -15.22 Mn |
| Jun 30, 2025 | -24.39 Mn |
| Mar 31, 2025 | -33.26 Mn |
| Dec 31, 2024 | -31.28 Mn |
| Sep 30, 2024 | -26.28 Mn |
| Jun 30, 2024 | -28.12 Mn |
| Mar 31, 2024 | -33.76 Mn |
| Dec 31, 2023 | -37.81 Mn |
| Sep 30, 2023 | -31.26 Mn |
| Jun 30, 2023 | -29.57 Mn |
| Mar 31, 2023 | -30.90 Mn |
| Dec 31, 2022 | -33.87 Mn |
| Sep 30, 2022 | -30.84 Mn |
| Jun 30, 2022 | -42.91 Mn |
| Mar 31, 2022 | -34.59 Mn |
| Dec 31, 2021 | 46.96 Mn |
| Sep 30, 2021 | -43.81 Mn |
| Jun 30, 2021 | -49.05 Mn |